For adenocarcinoma, the dominant histological subtype of lung cancer, increased understanding of molecular pathogenesis such as EGFR mutation, KRAS mutation and ALK fusion leads to the success of targeted therapy3. This evidence concerns the gene ALK and adenocarcinoma.